iRhythm Technologies, Inc. (IRTC)
NASDAQ: IRTC · Real-Time Price · USD
137.80
+0.10 (0.07%)
At close: May 12, 2025, 4:00 PM
135.10
-2.70 (-1.96%)
After-hours: May 12, 2025, 4:46 PM EDT
iRhythm Technologies Revenue
iRhythm Technologies had revenue of $158.68M in the quarter ending March 31, 2025, with 20.27% growth. This brings the company's revenue in the last twelve months to $618.59M, up 20.54% year-over-year. In the year 2024, iRhythm Technologies had annual revenue of $591.84M with 20.13% growth.
Revenue (ttm)
$618.59M
Revenue Growth
+20.54%
P/S Ratio
6.98
Revenue / Employee
$309,294
Employees
2,000
Market Cap
4.40B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 591.84M | 99.16M | 20.13% |
Dec 31, 2023 | 492.68M | 81.76M | 19.90% |
Dec 31, 2022 | 410.92M | 88.10M | 27.29% |
Dec 31, 2021 | 322.83M | 57.66M | 21.74% |
Dec 31, 2020 | 265.17M | 50.61M | 23.59% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IRTC News
- 10 days ago - Zio Demand Drives 20% Revenue Growth For iRhythm, Bullish Sentiment Builds Among Analysts - Benzinga
- 10 days ago - iRhythm Technologies, Inc. (IRTC) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - iRhythm Launches Zio® Long-Term Continuous Monitoring Service in Japan as the Zio® ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection - GlobeNewsWire
- 13 days ago - iRhythm Technologies to Present at the Bank of America Securities 2025 Health Care Conference - GlobeNewsWire
- 14 days ago - iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring - GlobeNewsWire
- 25 days ago - iRhythm Technologies to Report First Quarter 2025 Financial Results on May 1, 2025 - GlobeNewsWire
- 26 days ago - iRhythm Technologies Releases 2024 Corporate Sustainability Report That Demonstrates Ongoing Commitment to Culture of Quality and Sustainability - GlobeNewsWire
- 6 weeks ago - iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio® Long-Term Continuous Monitoring for Arrhythmia Detection - GlobeNewsWire